MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Ventyx Biosciences Inc

Open

1.25 5.04

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.21

Max

1.27

Belangrijke statistieken

By Trading Economics

Inkomsten

5.9M

-29M

EPS

-0.41

Werknemers

79

EBITDA

6.1M

-32M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+1221.55% upside

Dividenden

By Dow Jones

Volgende Winsten

8 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-29M

80M

Vorige openingsprijs

-3.79

Vorige sluitingsprijs

1.25

Ventyx Biosciences Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 sep 2024, 12:43 UTC

Belangrijke Marktbewegers

Ventyx Biosciences Shares Rise Premarket on Sanofi Investment

Peer Vergelijking

Prijswijziging

Ventyx Biosciences Inc Prognose

Koersdoel

By TipRanks

1221.55% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 15.33Ā USDĀ  1221.55%

Hoogste 21Ā USD

Laagste 11Ā USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Ventyx Biosciences Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

4

Buy

1

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Ventyx Biosciences Inc

Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.